FAGR Fagron SA

Fagron’s share buy-back program: Weekly update

Fagron’s share buy-back program: Weekly update

Regulated information

Nazareth (Belgium)/Rotterdam (The Netherlands), 7 November 2025 – 6PM CET

Fagron’s share buy-back program: Weekly update

In the period from 3 November 2025 through 7 November 2025, Fagron purchased 45,000 of its owns shares at an average price of €20.4413 per share corresponding to a total amount of €919,856.70.

These purchases are part of the share buy-back program of up to 200,000 Fagron shares to fulfill Fagron’s obligations under its long-term incentive scheme, which was announced on 9 October 2025.

The total number of own shares purchased to date is 156,000.

More information, including a detailed overview of the purchase transactions under this program, is available on our .

Financial calendar

12 February 2026                Full year results 2025

9 April 2026                         Trading update first quarter 2026

11 May 2026                        Annual General Meeting 2025

30 July 2026                         Half year results 2026

8 October 2026                        Trading update third quarter 2026

Further information

Ignacio Artola

Global Investor Relations Leader

About Fagron

Fagron is the leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in more than 35 countries around the world.

The Belgian company Fagron NV is based on Venecoweg 20A in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational activities are managed through the Dutch company Fagron BV. Fagron BV’s head office is located in Rotterdam.

Important information regarding forward-looking statements

Certain statements in this press release may be deemed to be forward-looking. Such forward-looking statements are based on current expectations and are influenced by various risks and uncertainties. Consequently, Fagron cannot provide any guarantee that such forward-looking statements will, in fact, materialize and cannot accept any obligation to update or revise any forward-looking statement as a result of new information, future events or for any other reason.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

        

Attachment



EN
07/11/2025

Underlying

FAGRFagron SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Fagron SA

 PRESS RELEASE
Free
FAGR FAGRON SA

Disclosure of a transparency notification from AOC Pharma S.à r.l.

Disclosure of a transparency notification from AOC Pharma S.à r.l. Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 27 02 2026 – 6PM CET Disclosure of a transparency notification from AOC Pharma S.à r.l. Pursuant to the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in listed companies, Fagron received a transparency notification from AOC Pharma S.à r.l., dated 24 February 2026. Notification from AOC Pharma S.à r.l. On 24 February 2026, Fagron received a transparency notification from AOC Pharma S.à r.l., informing the Company that its sharehold...

16h / 49m 1 EN
 PRESS RELEASE
Free
FAGR FAGRON SA

Openbaarmaking van transparantiekennisgeving van AOC Pharma S.à r.l.

Openbaarmaking van transparantiekennisgeving van AOC Pharma S.à r.l. Gereglementeerde informatie Nazareth (België)/Rotterdam (Nederland), 27 februari 2026 – 18:00 CET Openbaarmaking van transparantiekennisgeving van AOC Pharma S.à r.l. Overeenkomstig de Belgische Wet van 2 mei 2007 op de openbaarmaking van belangrijke deelnemingen in beursgenoteerde vennootschappen, ontving Fagron een transparantiekennisgeving van AOC Pharma S.à r.l., gedateerd 24 februari 2026. Kennisgeving van AOC Pharma S.à r.l. Op 24 februari 2026 ontving Fagron een transparantiekennisgeving van AOC Pharma S.à r.l....

16h / 49m 1 EN
ING Helpdesk
  • ING Helpdesk
PROX Proximus SA de ...
FAGR FAGRON SA ... (+7)

Benelux Morning Notes

Ackermans & van Haaren: Results capping already strong subsidiary reporting. DPS beat. Fagron: Acquisition of Pharmavit Europe, active in nutraceutical raw materials. Fugro: Patience please. Kendrion: Sees signs of improvement in EU economy. Proximus: 2026 dividend halved, 2028-30 targets a bit better on lower capex. Proximus: 4Q25 in line EBITDA on weaker sales, FCF up; 2026 guidance below on EBITDA. Recticel: Strong FY25 results, CEO transition seen as a negative

PROX PROXIMUS SA DE DROIT PUBLIC
FAGR FAGRON SA
REC RECTICEL SA
ACKB ACKERMANS & VAN HAAREN NV
KENDR KENDRION NV
OBEL ORANGE BELGIUM SA
FUR FUGRO NV
02/27/26 February 27, 2026 1 EN
Guy Sips ... (+7)
  • Guy Sips
  • Hilde Van Boxstael
  • Livio Luyten
  • Mathijs Geerts Danau
  • Michiel Declercq
  • Wim Hoste
  • Wim Lewi
PROX Proximus SA de ...
MTLS MATERIALISE ADS ... (+8)

Morning Notes : ACKB BB, FAGR BB, FUR NA, MTLS US, MDXH BB, PROX BB, R...

: ACKB BB, FAGR BB, FUR NA, MTLS US, MDXH BB, PROX BB, RECT BB, WHATS BB

PROX PROXIMUS SA DE DROIT PUBLIC
MTLS MATERIALISE ADS
FAGR FAGRON SA
TERB TER BEKE N.V.
REC RECTICEL SA
ACKB ACKERMANS & VAN HAAREN NV
FUR FUGRO NV
MDXH MDXHEALTH
02/27/26 February 27, 2026 1 EN
 PRESS RELEASE
Free
FAGR FAGRON SA

Fagron completes strategic acquisition of Pharmavit Europe, strengthen...

Fagron completes strategic acquisition of Pharmavit Europe, strengthening its leadership in high‑growth nutraceutical ingredients across EMEA Regulated information – inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 26 February 2026 – 6:30PM Fagron completes strategic acquisition of Pharmavit Europe, strengthening its leadership in high‑growth nutraceutical ingredients across EMEA Fagron, the leading global player in pharmaceutical compounding, announces that it has completed the acquisition of Pharmavit Europe, a leading European distributor of nutraceutical raw material...

February 26, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch